Chimeric Antigen Receptor Plasmid Production By Escherichia Coli Fermentation Using The SciVario® Twin Bioprocess Control System

By Ying Yang, Ma Sha, and Jorge Escobar

Advancing chimeric antigen receptor (CAR) cell therapy development demands precise, scalable bioprocess control from early research through clinical manufacturing. Integrating single-use bioreactor technology with flexible control systems helps streamline this transition, enabling consistent cell expansion while reducing contamination risk and operational complexity. Leveraging parallel bioreactor configurations, teams can optimize parameters such as agitation, gas transfer, and nutrient delivery across multiple runs, accelerating process development timelines. The combination of intuitive software and robust hardware design supports reproducibility and data-driven decision-making—critical factors for bringing cell therapies to market. Explore how modern single-use platforms are enabling efficient scale-up strategies and more reliable CAR cell production outcomes.